BriaCell announces board member resignation By Investing.com

BriaCell Therapeutics Corp. (NASDAQ:BCTX), a company specializing in pharmaceutical preparations, recently announced the departure of Marc Lustig from its board of directors. The resignation became effective on Saturday, November 23, 2024, according to a recent SEC filing.

The company, headquartered in West Vancouver, British Columbia, expressed its gratitude to Mr. Lustig for his significant contributions during his tenure on the board. However, the filing did not provide further details about the reasons for his departure or information about a successor.

Known for its focus on developing treatments in the pharmaceutical sector, BriaCell is listed on The Nasdaq Stock Market under the ticker symbols BCTX for its common shares and BCTXW for its warrants to purchase common shares.

In recent developments, BriaCell Therapeutics has made significant progress in the treatment of metastatic breast cancer. A Phase 2 clinical trial of its Bria-IMT regimen showed a notable improvement in progression-free survival, which was recognized by H.C. Wainwright, who maintained a Buy rating for the company and adjusted its price target to $15.00.

Furthermore, the FDA has approved an Expanded Access Program for Bria-IMT, aiming to increase the number of patients treated with Bria-IMT and potentially provide additional patient efficacy data alongside the ongoing Phase 3 trial. Recent analysis of the Phase 2 study’s overall survival data has bolstered H.C. Wainwright’s optimism.

Briacell also announced a partnership with BeiGene Ltd. (NASDAQ:BGNE) to conduct a clinical trial for a new cancer treatment involving Bria-OTS, Briacell’s novel immunotherapy. However, the company received a non-compliance notice from the Nasdaq Stock Market due to its share price falling below the minimum bid price, with a deadline until February 18, 2025, to address the issue.

InvestingPro Insights provide a glimpse into BriaCell Therapeutics Corp.’s financial standing amid the board shakeup. The company’s market capitalization is currently at $24.1 million, reflecting its position in the pharmaceutical sector. According to InvestingPro Tips, BCTX is “quickly burning through cash” and has not been profitable in the last twelve months, which may have contributed to the recent leadership changes. Operating income for the last twelve months was -$33.33 million, highlighting financial challenges.

Despite these obstacles, BCTX has shown a significant return over the last week, with a 22.64% price increase. However, the stock has seen a -49.33% price return over the last six months. For a more comprehensive analysis, InvestingPro offers 11 additional tips to provide valuable insights into BCTX’s financial health and market position.